Hydroxychloroquine alone is generally not recommended for the treatment of early connective tissue disease, which can be treated in combination with glucocorticoids such as prednisone acetate tablets or other immunosuppressants such as methotrexate. Hydroxychloroquine tablets are effective in treating patients suffering from significant skin and mucous membrane damage, joint and muscle lesions such as joint pain and swelling. Hydroxychloroquine is a traditional immunosuppressant, which has the effect of controlling the disease and slowing down the progress of the patient’s condition, and is also used as an adjunctive treatment for conditions such as thrombocytopenia. Hydroxychloroquine can reduce immunoglobulin, which has a good immunosuppressive effect on the treatment of connective tissue disease, and is mostly used in the adjuvant treatment of early connective tissue disease. Therefore, the treatment of early connective tissue disease is not recommended to rely on hydroxychloroquine alone, according to the needs of the disease may also need to be combined with glucocorticosteroids such as prednisone acetate tablets, etc. or other immunosuppressants such as methotrexate, leflunomide, etc. to achieve good therapeutic effect. The dosage of hydroxychloroquine should be followed as prescribed by the doctor. Hydroxychloroquine may cause adverse symptoms such as anorexia, diarrhea, dizziness and tinnitus. It is recommended that patients suffering from gastrointestinal diseases, cardiovascular diseases and allergic to the drug should not take it. The use of drugs need to follow the doctor’s instructions, patients with early connective tissue disease, should be promptly in the rheumatologist under the guidance of treatment.